Skip to main content

Diagnostics Play a Critical Role in Mitigating Fungal Infections

Fungal Infections

bioMérieux solutions maximize efficiency in the microbiology laboratory to help providers diagnose and mitigate fungal infections accurately and quickly for better patient outcomes.

Request Information

What are Fungal Infections and How Does Resistance Impact Treatment?

Fungal infections are becoming increasingly common and fungi’s growing resistance to antifungal treatments poses a serious threat to public health. With only four classes of antifungal medicines currently available and just a few new candidates in the clinical pipeline, it is imperative that healthcare facilities prescribe antifungal drugs appropriately, test for resistant fungi in patients who are not improving and are aware of resistance in their facilities and communities.1

One factor that is threatening to make several infection-causing fungi more widespread is climate change. Climate change can increase the geographic range of pathogenic species or their vectors, leading to the emergence of diseases in areas where they have not previously been reported.2

The invasive forms of fungal infections often affect severely ill patients and those with significant underlying immune system related conditions. Populations at greatest risk of invasive fungal infections include those with cancer, HIV/AIDS, organ transplants, chronic respiratory disease, and post-primary tuberculosis infection.3 While the most common pathogenic yeast species is Candida albicans, it is important to consider other species including Candida auris – which the World Health Organization (WHO) has identified as a fungal pathogen of critical priority. 

The rise of Candida auris is alarming as it is a yeast that is often-multidrug resistant and can cause invasive infections and outbreaks in healthcare facilities that are difficult to mitigate.4

Our Solution for Diagnosing Fungal Infections

Early diagnosis of fungal infections and the implementation of appropriate treatment contribute greatly to improved outcomes for patients. Every minute counts to identify patients at high risk of a life-threatening condition. It is important to rapidly identify Candida infections in positive blood culture, alongside other potential pathogens using a syndromic approach. Septic patients with polymicrobial and fungal infections are extremely critical and often have the highest mortality rate compared to other types of bloodstream infections. It is also important to consider that joints can be impacted by fungal infections commonly in prosthetics but sometimes in native joints.5

Solutions Overview

  • Fungi Identification: Our CHROMID® offer for fungi detection is unique with direct identification of the most prevalent Candida Albicans pathogen within 24-hours. It means faster time to results for patients in critical care.
  • Bloodstream Infections: The BIOFIRE® BCID2 Panel will identify seven fungal infection pathogens, alongside 26 other organisms commonly found in bloodstream infections. The BIOFIRE® BCID2 Panel has minimal hands-on time, with results in about an hour, helping microbiologists and clinicians quickly identify the causative pathogen in a patient suspected of a fungal infection in positive blood culture.
  • Joint Infections: Conventional testing for joint infections is complex, often requiring multiple patient samples, various send-out tests, and days of waiting for results. The BIOFIRE® Joint Infection Panel is a rapid syndromic test that delivers comprehensive results in about ~1 hour.  With 2 fungal, 29 Bacterial, and 8 AMR targets, the BIOFIRE® JI Panel can facilitate improved management of fungal and polymicrobial detections.

Fungal Infections – Our Diagnostic Offer

We offer flexible options for identification of fungal infection pathogens. Additionally, integration of bioMérieux solutions can help to maximize efficiency in the microbiology laboratory with innovative automation and efficient use of IT solutions that will ensure the right information is in the right hands as quickly as possible.

Disclaimer: Product availability varies by country.  Please consult your local bioMérieux representative for product availability in your country.

  • VIDAS® KUBE™

    Stackable benchtop automated immunoassay solution

    VIDAS® KUBE™ is designed to preserve everything labs appreciate about the VIDAS® Solution combined with advanced technology. VIDAS® KUBE™ is a truly flexible, cost-effective automated immunoassay solution providing fast results in complete confidence.

    View Product

  • VIDAS® NEPHROCHECK®

    Reveal Kidney Stress Early. Drive Better Outcomes.

    VIDAS® NEPHROCHECK® measures urinary TIMP-2 & IGFBP-7, specific urinary biomarkers for early risk assessment of moderate to severe Acute Kidney Injury (AKI). The VIDAS® NEPHROCHECK® assay is intended to be used in conjunction with clinical evaluation as an aid in the risk assessment for moderate or severe acute kidney injury (AKI) in acutely ill patients.

    View Product

  • VIDAS® NT-proBNP 2

    Exclusion or Confirmation of Acute Heart Failure

    VIDAS® NT-proBNP2 is a useful tool for rapid and clinical assessment and diagnosis of patients with symptoms of suspected heart failure.

    High sensitivity and specificity allows initiation of timely, appropriate treatment.

    Cost-effective tool adapted to emergency situations.

    View Product

  • VIDAS® SARS-COV-2 

    Two immunoassay tests to detect IgM & IgG antibodies

    VIDAS® SARS-COV-2 IgM and VIDAS® SARS-COV-2 IgG II automated qualitative assays rapidly detect antibodies to help identify individuals with previous exposure to SARS-CoV-2.

    View Product

  • VIDAS® TB-IGRA

    Reliable and fully automated solution for Tuberculosis (TB) infection detection


    Available on the VIDAS® 3 immunoanalyzer, VIDAS® TB-IGRA is a whole-blood test for the diagnosis of Mycobacterium tuberculosis infection.

    View Product

  • VIDAS® TBI (GFAP, UCH-L1)

    RULES-OUT Intracranial Lesions for mild Traumatic Brain Injury

    Fast all-in-one test kit based on blood brain biomarkers to predict absence of intracranial lesions in mild Traumatic Brain Injury patients and objectively assess the need for a head CT-scan.

    View Product

  • VIDAS® Thyroid Assays

    A Full Panel for the Investigation of Thyroid Diseases

    The VIDAS® Thyroid panel includes 8 automated tests to aid clinicians in the diagnosis and treatment monitoring of thyroid disorders.

    View Product

  • VIDAS® ToRC Panel

    Serenity throughout Pregnancy

    The VIDAS® ToRC panel included 9 automated tests for the screening and diagnosis of toxoplasmosis, rubella, and cytomegalovirus (CMV) infections.  

    View Product

  • VIDAS® Tumour Markers

    Diagnosis and Treatment Monitoring of Various Cancers

    The VIDAS® panel of Tumour Markers offers a rapid, automated, precise, and reliable solution to meet your diagnostic needs.

    View Product

  • VIDAS® B•R•A•H•M•S PCT™

    Important Biomarker for Improved Patient Management

    Detects procalcitonin, a biomarker that aids in the risk assessment for progression to severe sepsis and septic shock. PCT also aids in decision making on antibiotic therapy for patients with lower respiratory tract infections (LRTI).

    View Product

  • VILINK®

    Optimize Instrument UPTIME to Improve Laboratory Productivity

    A secure solution offering remote access, proactive maintenance, and remote updates. VILINK® diagnoses, solves software and instrument issues, and supports your systems to enable laboratory productivity and efficiency improvements. 

    View Product

  • VITEK® 2

    Fully integrated Identification and Antimicrobial Susceptibility Testing

    VITEK® 2, the leading automated system for routine antimicrobial susceptibility testing, provides efficient workflow, faster AST results. Its fully-integrated ID & AST approach ensures superior performance to rapidly and confidently guide therapy.

    View Product

  • VITEK® 2 COMPACT

    Compact, automated ID/AST instrument

    The compact solution for fast, accurate ID/AST testing with expert confidence

    View Product

  • VITEK® 2 ID & AST Cards

    Rapid. Flexible. Efficient.

    Providing accurate and reliable identification and antimicrobial susceptibility results for clinically relevant organisms with self-contained, disposable test cards designed for VITEK® 2 automated systems.

    View Product

  • VITEK® MS

    Microbial Identification in Minutes

    VITEK® MS provides rapid and robust identification of microorganisms delivering clinicians with actionable results to support informed treatment decisions.

    View Product

Useful Resources for Fungal Infection Diagnostics

Samples. Pathogens. Decisions. Culture of Confidence

Leading the Charge on Multi-Drug Resistant Organisms in Culture Identification

Download PDF

Contact Us for Information on Our Solutions for Fungal Infections

      

    References

    1. Antimicrobial-Resistant Fungi | Fungal Diseases | CDC. (2022, September 30). Www.cdc.gov. https://www.cdc.gov/fungal/antifungal-resistance.html#tackling

    2. Nnadi, N. E., & Carter, D. A. (2021). Climate change and the emergence of fungal pathogens. PLOS Pathogens, 17(4), e1009503. https://doi.org/10.1371/journal.ppat.1009503

    3. WHO releases first-ever list of health-threatening fungi. (2022, October 25). Www.who.int. https://www.who.int/news/item/25-10-2022-who-releases-first-ever-list-of-health-threatening-fungi

    4. Ahmad, S., & Alfouzan, W. (2021). Candida auris: Epidemiology, Diagnosis, Pathogenesis, Antifungal Susceptibility, and Infection Control Measures to Combat the Spread of Infections in Healthcare Facilities. Microorganisms, 9(4), 807. https://doi.org/10.3390/microorganisms9040807

    5. Mishra, A., & Juneja, D. (2023). Fungal arthritis: A challenging clinical entity. World Journal of Orthopedics, 14(2), 55–63. https://doi.org/10.5312/wjo.v14.i2.55